Sugi Predict

Sugi Predict / Compounds / SCHEMBL8344151

SCHEMBL8344151

SCHEMBL8344151

Oc1ccc(/C=C/c2ccc3cccc(O)c3n2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CD74 P04233 1/20 1.00
▸ MIF P14174 1/20 1.00
▸ MEN1 O00255 14/20 0.73
▸ KMT2A Q03164 14/20 0.73
▸ NPC1 O15118 13/20 0.73
▸ RAB9A P51151 10/20 0.72
▸ KDM4E B2RXH2 5/20 0.72
▸ SMN1; SMN2 Q16637 5/20 0.72
▸ MAPT P10636 4/20 0.72
▸ LMNA P02545 3/20 0.72
▸ HTT P42858 3/20 0.72
▸ POLB P06746 2/20 0.72
▸ PKM P14618 1/20 0.72
▸ NFKB1 P19838 1/20 0.72
▸ NFKB2 Q00653 1/20 0.72
▸ RELA Q04206 1/20 0.72
▸ HSP90AA1 P07900 4/20 0.68
▸ OPRK1 P41145 1/20 0.63
▸ L3MBTL1 Q9Y468 2/20 0.62
▸ ALDH1A1 P00352 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3317100 0.89 CD74 (0.79) CD74MIFMEN1KMT2ANPC1
SCHEMBL3319480 0.89 CD74 (0.79) CD74MIFMEN1KMT2ANPC1
SCHEMBL28200632 0.87 CD74 (0.77) CD74MIFMEN1KMT2ANPC1
SCHEMBL6428720 0.87 CD74 (0.77) CD74MIFMEN1KMT2ANPC1
SCHEMBL28473985 0.86 CD74 (0.75) CD74MIFMEN1KMT2ANPC1
SCHEMBL28473988 0.86 CD74 (0.75) CD74MIFMEN1KMT2ANPC1
SCHEMBL3854732 0.84 MEN1 (0.77) CD74MIFMEN1KMT2ANPC1
SCHEMBL7691066 0.84 MEN1 (0.76) CD74MIFMEN1KMT2ANPC1
SCHEMBL7691068 0.84 MEN1 (0.76) CD74MIFMEN1KMT2ANPC1
SCHEMBL29084196 0.84 CD74 (0.72) CD74MIFMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 — — US disclosed
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 — — US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 — — US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 — — US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 — — US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 — — US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 — — US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 — — US disclosed
US-9163018-B2 Method of treatment of age-related macular degeneration (AMD) PRANA BIOTECHNOLOGY INC. (AU) 2015-10-20 — — US disclosed
US-9163018-B2 Method of treatment of age-related macular degeneration (AMD) PRANA BIOTECHNOLOGY INC. (AU) 2015-10-20 — — US disclosed
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME PRANA BIOTECHNOLOGY LIMITED (AU) 2010-03-18 — — US disclosed
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME PRANA BIOTECHNOLOGY LIMITED (AU) 2010-03-18 — — US disclosed
US-7619091-B2 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) PRANA BIOTECHNOLOGY LIMITED (AU) 2009-11-17 — — US disclosed
US-7619091-B2 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) PRANA BIOTECHNOLOGY LIMITED (AU) 2009-11-17 — — US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 — — US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 — — US disclosed
WO-2007147217-A1 METHOD OF TREATMENT OF GLIOMA BRAIN TUMOUR PRANA BIOTECHNOLOGY LIMITED (AU) 2007-12-27 — — WO disclosed
US-20070037848-A1 Treatment of neurological conditions PRANA BIOTECHNOLOGY LTD. (AU) 2007-02-15 — — US disclosed
US-20070037848-A1 Treatment of neurological conditions PRANA BIOTECHNOLOGY LTD. (AU) 2007-02-15 — — US disclosed
WO-2004007461-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2004-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME MGMT, DHFR, IDH2 CD74 804/4885MIF 1650/4885MEN1 83/4885
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN CD74 4185/4885MIF 2900/4885MEN1 1871/4885
US-20080161353-A1 8-Hydroxy quinoline derivatives PARK7, COQ8A, NLN CD74 4185/4885MIF 2900/4885MEN1 1871/4885
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression TERT, TERF2, RNGTT CD74 4319/4885MIF 4807/4885MEN1 3550/4885
US-20070037848-A1 Treatment of neurological conditions BDNF, NLN, TXNRD2 CD74 2293/4885MIF 896/4885MEN1 2861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.